Kahira Pharmaceuticals & Chemical Industries Past Earnings Performance
Past criteria checks 5/6
Kahira Pharmaceuticals & Chemical Industries has been growing earnings at an average annual rate of 11.5%, while the Pharmaceuticals industry saw earnings growing at 11.5% annually. Revenues have been growing at an average rate of 3.7% per year. Kahira Pharmaceuticals & Chemical Industries's return on equity is 30%, and it has net margins of 17.1%.
Key information
11.5%
Earnings growth rate
10.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 9.8% |
| Revenue growth rate | 3.7% |
| Return on equity | 30.0% |
| Net Margin | 17.1% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Kahira Pharmaceuticals & Chemical Industries makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,385 | 236 | 109 | 0 |
| 30 Sep 23 | 1,088 | 117 | 105 | 0 |
| 30 Jun 23 | 1,005 | 97 | 104 | 0 |
| 31 Mar 23 | 911 | 71 | 104 | 0 |
| 30 Sep 22 | 1,105 | 168 | 106 | 0 |
| 30 Jun 22 | 1,112 | 166 | 102 | 0 |
| 31 Mar 22 | 1,120 | 172 | 100 | 0 |
| 31 Dec 21 | 1,057 | 139 | 95 | 0 |
| 30 Sep 21 | 1,033 | 127 | 89 | 0 |
| 30 Jun 21 | 1,062 | 124 | 88 | 0 |
| 31 Mar 21 | 1,042 | 120 | 98 | 0 |
| 31 Dec 20 | 1,028 | 119 | 97 | 0 |
| 30 Sep 20 | 1,049 | 117 | 101 | 0 |
| 30 Jun 20 | 1,010 | 109 | 99 | 0 |
| 31 Mar 20 | 999 | 105 | 103 | 0 |
| 31 Dec 19 | 972 | 98 | 104 | 0 |
| 30 Sep 19 | 950 | 80 | 108 | 0 |
| 30 Jun 19 | 963 | 85 | 108 | 0 |
| 31 Mar 19 | 983 | 101 | 101 | 0 |
| 31 Dec 18 | 963 | 100 | 100 | 0 |
| 30 Sep 18 | 925 | 113 | 97 | 0 |
| 30 Jun 18 | 863 | 108 | 95 | 0 |
| 31 Mar 18 | 801 | 105 | 118 | 0 |
| 31 Dec 17 | 747 | 99 | 108 | 0 |
| 30 Sep 17 | 721 | 98 | 95 | 0 |
| 30 Jun 17 | 690 | 88 | 86 | 0 |
| 31 Mar 17 | 640 | 74 | 42 | 0 |
| 31 Dec 16 | 598 | 58 | 43 | 0 |
| 30 Sep 16 | 562 | 49 | 43 | 0 |
| 30 Jun 16 | 517 | 42 | 42 | 0 |
| 31 Mar 16 | 500 | 45 | 43 | 0 |
| 31 Dec 15 | 491 | 48 | 41 | 0 |
| 30 Sep 15 | 465 | 45 | 39 | 0 |
| 30 Jun 15 | 451 | 43 | 40 | 0 |
| 31 Mar 15 | 439 | 34 | 37 | 0 |
| 31 Dec 14 | 431 | 37 | 37 | 0 |
| 30 Sep 14 | 415 | 37 | 38 | 0 |
| 30 Jun 14 | 404 | 41 | 36 | 0 |
| 31 Mar 14 | 404 | 57 | 35 | 0 |
| 31 Dec 13 | 396 | 59 | 34 | 0 |
| 30 Sep 13 | 387 | 58 | 32 | 0 |
Quality Earnings: CPCI has a high level of non-cash earnings.
Growing Profit Margin: CPCI's current net profit margins (17.1%) are higher than last year (7.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CPCI's earnings have grown by 11.5% per year over the past 5 years.
Accelerating Growth: CPCI's earnings growth over the past year (233.7%) exceeds its 5-year average (11.5% per year).
Earnings vs Industry: CPCI earnings growth over the past year (233.7%) exceeded the Pharmaceuticals industry 54.7%.
Return on Equity
High ROE: CPCI's Return on Equity (30%) is considered high.